期刊
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
卷 99, 期 2, 页码 190-193出版社
AMER COLL ALLERGY ASTHMA IMMUNOLOGY
DOI: 10.1016/S1081-1206(10)60644-8
关键词
-
Background: Chronic urticaria (CU) is often difficult to treat. Approximately 40% to 50% of patients with no apparent cause are believed to have an associated autoimmune profile that may play a pathogenetic role. Objectives: To describe 3 patients with CU refractory to conventional treatment who responded to omalizumab therapy. Methods: Treatment was maximized with antihistamines, antileukotrienes, and histamine(2) blockers with no improvement. Systemic steroids provided only temporary relief. Laboratory workup revealed 1 patient with a low IgE level and elevated anti-IgE receptor antibody level, 1 patient with an elevated IgE level but a normal anti-IgE receptor antibody level, and 1 patient with a very elevated IgE level and an elevated anti-IgE receptor antibody level. All 3 patients were prescribed omalizumab therapy every 2 weeks. Results: Two patients had total clearing of urticaria within 1 week and 1 patient within 6 weeks of starting ornalizurnab therapy. The patient with the elevated anti-IgE receptor antibody level had normalization of the level after starting treatment. Conclusions: Omalizumab may have a beneficial effect in the treatment of CU. Further studies are needed to confirm this effect and better elucidate the mechanism for the observed improvement.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据